Human papillomavirus (HPV) can induce benign and malignant lesions. It is involved in almost all cervix carcinoma and in an increasing amount of head and neck cancers. Cidofovir (CDV) was found to be efficacious in treatment of HPV related hyperplasias. It has been shown that inhibition of cell proliferation contributes to the effects of CDV and has been associated with apoptosis induction, cell cycle arrest and increased levels of tumor suppressor proteins. Evaluation of the effect of CDV by means of microarray suggested that CDV causes DNA damage. Moreover, we found that CDV incorporates in genomic DNA. In this study we evaluated whether a correlation between DNA-incorporation and the anti-proliferative effect caused by CDV exists. This ...
Acyclic nucleoside phosphonates (ANPs) are well-known for their antiviral properties, three of them ...
Objectives: Cidofovir (CDV) is known to have antiproliferative effects on HPV+ transformed cells. Cl...
The FDA-approved anti-DNA virus agent cidofovir (CDV) is being evaluated in phase II/III clinical tr...
Human papillomavirus (HPV) can induce benign and malignant lesions. It is involved in almost all cer...
Human papillomavirus (HPV) can induce both benign and malignant lesions. It is involved in almost al...
Introduction: Human papillomavirus (HPV) can induce both benign and malignant hyper proliferations. ...
Human papillomavirus (HPV) causes cervical cancer and a large fraction of head and neck squamous cel...
Cidofovir (CDV) proved efficacious in treatment of human papillomaviruses (HPVs) hyperplasias. Antip...
Cidofovir (CDV) is an antiviral agent with antiproliferative properties. The aim of our study was to...
Human papillomaviruses (HPVs) are double-stranded DNA viruses of which the mucosal alpha-types can i...
Insights into the mechanisms associated with chemotherapy-resistance are important for implementatio...
Human papillomaviruses (HPVs) are double-stranded DNA viruses of which the mucosal alpha-types can i...
Human papillomavirus (HPV) is responsible for cervical cancer, and its role in head and neck carcino...
Objectives: We have previously demonstrated that cidofovir (CDV) induces DNA damage and activates AT...
The anti-viral acyclic nucleoside monophosphate compound Cidofovir has shown efficacy in treatment o...
Acyclic nucleoside phosphonates (ANPs) are well-known for their antiviral properties, three of them ...
Objectives: Cidofovir (CDV) is known to have antiproliferative effects on HPV+ transformed cells. Cl...
The FDA-approved anti-DNA virus agent cidofovir (CDV) is being evaluated in phase II/III clinical tr...
Human papillomavirus (HPV) can induce benign and malignant lesions. It is involved in almost all cer...
Human papillomavirus (HPV) can induce both benign and malignant lesions. It is involved in almost al...
Introduction: Human papillomavirus (HPV) can induce both benign and malignant hyper proliferations. ...
Human papillomavirus (HPV) causes cervical cancer and a large fraction of head and neck squamous cel...
Cidofovir (CDV) proved efficacious in treatment of human papillomaviruses (HPVs) hyperplasias. Antip...
Cidofovir (CDV) is an antiviral agent with antiproliferative properties. The aim of our study was to...
Human papillomaviruses (HPVs) are double-stranded DNA viruses of which the mucosal alpha-types can i...
Insights into the mechanisms associated with chemotherapy-resistance are important for implementatio...
Human papillomaviruses (HPVs) are double-stranded DNA viruses of which the mucosal alpha-types can i...
Human papillomavirus (HPV) is responsible for cervical cancer, and its role in head and neck carcino...
Objectives: We have previously demonstrated that cidofovir (CDV) induces DNA damage and activates AT...
The anti-viral acyclic nucleoside monophosphate compound Cidofovir has shown efficacy in treatment o...
Acyclic nucleoside phosphonates (ANPs) are well-known for their antiviral properties, three of them ...
Objectives: Cidofovir (CDV) is known to have antiproliferative effects on HPV+ transformed cells. Cl...
The FDA-approved anti-DNA virus agent cidofovir (CDV) is being evaluated in phase II/III clinical tr...